WAP
GNMX

Wealthcare Advisory Partners’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Wealthcare Advisory Partners’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,000
Closed -$10K – 1355
2018
Q1 		$10K Hold
5,000
– – ﹤0.01% 740
2017
Q4 		$6K Hold
5,000
– – ﹤0.01% 771
2017
Q3 		$6K Buy
+5,000
New +$6.39K ﹤0.01% 627

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Wealthcare Advisory Partners's GNMX Position: Q2 2018 in Review

Wealthcare Advisory Partners sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2018, closing a stake of 5,000 shares — an estimated $10K sold.

Wealthcare Advisory Partners first reported a position in GNMX in Q3 2017 and held it in 3 quarters. The position peaked at $10K in Q1 2018. 40 funds tracked by Wall St. Rank hold GNMX as of Q2 2018.

  • Wealthcare Advisory Partners reported no remaining Aevi Genomic Medicine Inc position as of Q2 2018 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 5,000 Aevi Genomic Medicine Inc shares in Q2 2018, an estimated $10K.
  • Wealthcare Advisory Partners first reported a position in Aevi Genomic Medicine Inc in Q3 2017 and held it in 3 quarters.
  • Wealthcare Advisory Partners's Aevi Genomic Medicine Inc position peaked at $10K in Q1 2018.
  • 40 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2018, filed 14 Aug 2018.